Kopač, P.; Koren, A.; Bidovec-Stojkovič, U.; Košnik, M.; Dejanović, L.; Mesti, T.; Strojan, P.; Korošec, P.; Ocvirk, J.
Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients. Diagnostics 2024, 14, 1403.
https://doi.org/10.3390/diagnostics14131403
AMA Style
Kopač P, Koren A, Bidovec-Stojkovič U, Košnik M, Dejanović L, Mesti T, Strojan P, Korošec P, Ocvirk J.
Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients. Diagnostics. 2024; 14(13):1403.
https://doi.org/10.3390/diagnostics14131403
Chicago/Turabian Style
Kopač, Peter, Ana Koren, Urška Bidovec-Stojkovič, Mitja Košnik, Luka Dejanović, Tanja Mesti, Primož Strojan, Peter Korošec, and Janja Ocvirk.
2024. "Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients" Diagnostics 14, no. 13: 1403.
https://doi.org/10.3390/diagnostics14131403
APA Style
Kopač, P., Koren, A., Bidovec-Stojkovič, U., Košnik, M., Dejanović, L., Mesti, T., Strojan, P., Korošec, P., & Ocvirk, J.
(2024). Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients. Diagnostics, 14(13), 1403.
https://doi.org/10.3390/diagnostics14131403
